Navigation Links
University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
Date:1/16/2013

AURORA, Colo. (PRWEB) January 16, 2013

Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation – most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.

A University of Colorado Cancer Center study published today in the Journal of Clinical Investigation shows that the protein SPARC (Secreted Protein Acidic and Rich in Cysteine) acts much like an anti-inflammatory drug, attempting to heal tissues inflamed by tumors. Likewise, cancers – for example, bladder cancer in this study – have developed ways to turn off the production of SPARC, thus allowing growth and metastasis, especially to the lung where bladder cancer is frequently fatal.

"In fact, we show the effects of SPARC go beyond even this anti-inflammatory role. Additionally, the protein is involved in disallowing migrating cancer cells from attaching at possible metastasis sites and stopping the production of new blood vessels needed to feed tumor tissue," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and the study's senior author.

The study started by evaluating SPARC levels in human bladder cancer samples. In less aggressive cancers, both the tumor and the surrounding tissue made SPARC. In more aggressive cancers, it was just the surrounding tissue that made SPARC – the aggressive tumor itself had suppressed production of the protein. In these human bladder cancer tumors, more SPARC was associated with longer survival.

This distinction between SPARC made in the tumor and SPARC made in the surrounding tissue largely explains previous work that found high SPARC in aggressive tumors and so suggested a possible tumor-promoting role for the protein. Instead, it
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Rice University discovers that graphene oxide soaks up radioactive waste
2. Carin Grings remains identified by researchers at Uppsala University
3. Nanonex Delivered Advanced Nanoimprint Tool NX-B200 to Swinburne University of Technology, Australia
4. University of Pennsylvania Purchases Nanonex Advanced Nanoimprint Tool NX-2600 BA
5. Eqalix Enters Sponsored Research Agreement with Temple University
6. Bed Bugs Find Their Way to University of Washington and Hastings-on-Hudson Libraries; Bed Bug Control 911 Advises Use of Bed Bug Spray to Effectively Clear the Pests Away
7. University of College London Hospitals (UCLH) Selects GEO SCAN Medical as New Standard of Care for the Detection and Treatment of Prostate Cancer
8. iLab Solutions Core Facility Management Software Named a University Business Magazine 2012 Readers’ Choice Top Product
9. Ben-Gurion University awarded $6.5 million grant to develop nano thin infrared night vision glasses
10. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
11. Moscow State University Hospital Selects Ekahau RTLS to Improve Operations and Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... Crystal Diagnostics (CDx) Xpress System, a rapid ... AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. coli ... to as STEC or the “Big-6”) as well as Escherichia ... per 325 g of raw ground beef and raw beef ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... Two Milestones Reached in Zonisamide Patent Portfolio -, ... (Nasdaq: OREX ), a biopharmaceutical company focused ... system-related disorders, today,announced the initiation of its first ... of zonisamide plus olanzapine.,The Phase 2a clinical trial, ...
... to be Indicated ... for Use in First-Line Therapy, SEATTLE, ... announced today that it has submitted a supplemental,Biologics License Application ... of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation therapy after remission induction in ...
... Laboratories, Inc.,(NYSE: FRX ), an international manufacturer ... 2009 Second Quarter financial results,before the U.S. stock ... that,day, at 10:00 AM EDT, Forest will host ... Chief Operating Officer and Frank Perier, Senior,Vice President-Finance ...
Cached Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 2
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... NEW ORLEANS (April 17, 2009) Secondhand tobacco smoke ... cardiovascular function of men and women who were exposed ... as 10 minutes, according to a study from the ... that tobacco smoke could possibly harm cardiovascular function. In ...
... genetics in high school has heard of adenine, thymine, guanine ... the DNA code. But those are not the whole story. ... attention to a fifth nucleotide, 5-methylcytosine (5-mC), that sometimes replaces ... genes are expressed. And now there,s a sixth. In ...
... it,s time X got some attention. In the ... female, University of California, Berkeley, biologist Doris Bachtrog and ... chromosome is every bit as interesting as the much-studied, ... origins and benefits of sexual reproduction. "Contrary to ...
Cached Biology News:Smoke from cigarettes, cooking oil, wood, shift male cardiovascular system into overdrive 2Smoke from cigarettes, cooking oil, wood, shift male cardiovascular system into overdrive 3New nucleotide could revolutionize epigenetics 2New nucleotide could revolutionize epigenetics 3New nucleotide could revolutionize epigenetics 4The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
... 293 cells were cultured in Minimum Essential Medium ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... Microsphere/Microarray Stabilizer is an aqueous solution that ... non-toxic chemicals in a PBS buffer (phosphate ... This product contains a combination of 0.02% ... StabilCoat Plus Stabilizer provides optimum performance ...
... Anti-PSD-95, clone K28/86.2, PDZ Domain ... Immunogen : GST fusion to residues ... 0.01M Tris pH 7.4, 0.075M NaCl ... routinely evaluated by immunoblot on rat ...
... Clarin represents the state-of-the-art in ... for the permanent preservation of immunohistochemical ... (DAB), Vega Red, New Fuchsin, and ... substrates on tissue sections. Clarin can ...
Biology Products: